The CMV market targets patients with immunodeficiencies, particularly patients receiving solid organ or hematopoietic stem cell transplants. Current therapies have strong antiviral activity but notable side effects, in particular myelotoxicity. These safety issues and a lack of alternative therapies contribute to the substantial unmet need for additional therapeutic options. Several companies are developing novel antivirals, adoptive cell therapies, and therapeutic and prophylactic vaccines to address various aspects of CMV. The anticipated launch of these agents is expected to transform the CMV space and give patients with high unmet need much-needed treatment options.

Table of contents

  • Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
      • Drivers and Constraints
        • What Factors Are Driving the Market for Cytomegalovirus?
        • What Factors Are Constraining the Market for Cytomegalovirus?
        • Specific Trends
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Key Findings
        • Expert Insight
        • Disease Overview
      • Etiology
        • CMV in SOT and HSCT Patients
        • Congenital CMV Infection
      • Pathophysiology
        • Evasion of Host Immune Responses
      • Clinical Presentation and Symptomology
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Expert Insights
        • Overview
      • Epidemiology Populations
        • Total HSCT Events with Increased Risk of CMV Syndrome or Disease
        • Total Solid-Organ Transplant Events with Increased risk of CMV Syndrome or Disease
        • Total Prevalent Cases of CMV Seropositive Pregnant Women
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Antivirals and Other Agents Prescribed for CMV
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment
    • Unmet Need Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in CMV
        • Future Attainment of Unmet Needs in CMV
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for CMV
      • Orphan Drug Designation
        • Orphan Drug Provisions: United States
        • Orphan Drug Provisions: Europe
      • Patient Registries
      • Key Emerging Therapies
        • Antivirals
        • Antivirals
        • Adoptive Cell Therapies
        • Therapeutic Vaccines
        • Adoptive Cell Therapies
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for CMV
        • Notable Developments in the Early-Phase Pipeline for CMV Infection
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
    • Methodology
      • Methodology
        • Bottom-Up Market Forecasting Overview
        • Patient Share and Sales Calculations
        • Drug-Treatment Rate Assumptions
        • Patient Share Assumptions
        • General Sources of Data
        • Dosing, Days of Therapy, and Compliance
        • Price per Treated Day and Course Assumptions, 2025
    • Appendix
      • Experts Interviewed
      • CMV Bibliography

Author(s): Michael Breen, PhD

Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas. Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.